Question-Based Review: An FDA Reviewer's Perspective - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Question-Based Review: An FDA Reviewer's Perspective
The author analyzes, from an agency perspective, whether question-based review has improved product quality or made the review process easier for regulators or for industry.


Pharmaceutical Technology
Volume 33, Issue 10

The Office of Generic Drugs (OGD) fully implemented Question-based Review (QbR) in 2007 with the broad goal of encouraging sponsors to include quality-by-design (QbD) principles in their product and process development and to communicate this knowledge in their submissions. In light of this goal, OGD outlined the following four major benefits that the QbR platform would bring to the chemistry, manufacturing, and controls (CMC) review process (1, 2):

  • Ensure product quality through product design and performance-based specifications
  • Facilitate continuous improvement and reduce CMC supplements through risk assessment
  • Enhance the quality, transparency, and consistency of reviews through standardized review questions
  • Reduce CMC review time when applicants submit a quality overall summary (QOS) that adequately addresses the QbR questions.


Table I: Key Question-based Review questions for process and product understanding (listed by section).
This article will provide a CMC reviewer's assessment of how QbR has contributed to achieving these benefits. The author will identify the current approach's strengths and areas for improvement within OGD and for sponsors of abbreviated new drug applications (ANDAs). The assessment and recommendations are based on the author's experience reviewing more than 20 QbR applications submitted during the past two years. The applications covered various dosage forms, including numerous modified-release drug products.

Ensuring product quality

Of the 37 questions in the current QbR QOS template, about 14 critical questions, most of which come from Section 3.2.P.2, are designed to encourage the sharing of product design and development information not typically included under the old CMC review paradigm. These questions incorporate QbD principles into the CMC review process and result in the most significant changes in the approach to product development and documentation suggested in a QbR ANDA for the sponsor and the reviewer. That is not to say that some information in these areas was not provided by sponsors and evaluated by CMC reviewers under the old review format. This information, however, was often provided only in response to agency queries or to correct deficiencies. Also, under the old paradigm, submissions and reviews in these areas were highly variable, thus no consistent basis for assessing process and product understanding was established. The QbR format has provided the necessary framework for sponsors to provide this information consistently and for CMC reviewers to assess this information critically.

Typically, the product development information that answers the critical QbR questions is incorporated into the ANDA as a Pharmaceutical Development Report (PDR). Incorporating the PDR into the ANDA review process is the most significant change brought about by the QbR approach because this information was almost entirely excluded under the old approach. The PDR provides the means for a sponsor to demonstrate to the reviewer its level of process and product understanding and provide the crucial link between the process, control testing, and specification choices in the final product to the data obtained during development on experimental and pilot-scale lots. Without a high-quality PDR that addresses these key questions in a meaningful way, the QbR amounts to little more than format change rather than the mechanism for communicating process and product understanding it was intended to be.

As previously pointed out, some QbR applications are accompanied by answers to these critical questions and PDRs that lack substantive information (3). Contrary to the intent of the critical QbR questions, some submissions demonstrate that QbD principles did not guide product and process development from the beginning and that sponsors have continued to test rather than design quality into their products. On the other hand, many high-quality submissions have incorporated QbD principles and thus benefited both the reviewer and the sponsor.

To realize the full extent of possible benefits for review quality and efficiency, it is imperative that sponsors provide meaningful answers to all of the relevant critical questions and submit PDRs that give a full scientific basis for them. The best product-development reports currently provided by sponsors possess the following common attributes:

  • Clearly support the sponsor's choices of critical quality attributes (CQAs) and critical process parameters (CPPs) with relevant experimental data.
  • Clearly present experimental design and clearly link it to the corresponding CQAs or CPPs with scientific rationales.
  • Present data to demonstrate why individual unit operations, specifications, or process parameters are or are not critical.
  • Present data from pilot batches of failing or suboptimal formulations or processes, offer an analysis of the issues and problems, and explain how this knowledge led to the optimized formulation or process. This information is especially useful for evaluating complicated products such as modified-release dosage forms.

Most QbR submissions stop short of using a design-of-experiments approach, often associated with QbD, to perform an extensive, systematic exploration of process parameters. However, a small number of experiments on laboratory-or pilot-scale lots in which carefully chosen critical variables are explored across a limited range is extremely useful in demonstrating process and product understanding. The experience gained by sponsors preparing high-quality PDRs will be helpful as OGD prepares to incorporate full QbD elements in the future (3–5). This transition will be much easier for sponsors who consistently provide high-quality PDRs with meaningful information.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here